Agricultural Inputs
Compare Stocks
4 / 10Stock Comparison
RKDA vs LIN vs APD vs PGEN
Revenue, margins, valuation, and 5-year total return — side by side.
Chemicals - Specialty
Chemicals - Specialty
Biotechnology
RKDA vs LIN vs APD vs PGEN — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | ||||
|---|---|---|---|---|
| Industry | Agricultural Inputs | Chemicals - Specialty | Chemicals - Specialty | Biotechnology |
| Market Cap | $2M | $228.85B | $65.68B | $1.22B |
| Revenue (TTM) | $5M | $34.66B | $12.46B | $6M |
| Net Income (TTM) | $-2M | $7.13B | $2.11B | $-247M |
| Gross Margin | 36.2% | 46.0% | 32.0% | 23.0% |
| Operating Margin | -51.4% | 28.8% | 18.4% | -18.6% |
| Forward P/E | — | 27.7x | 22.5x | — |
| Total Debt | $0.00 | $26.99B | $18.41B | $6M |
| Cash & Equiv. | $259K | $5.06B | $1.86B | $30M |
RKDA vs LIN vs APD vs PGEN — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| Arcadia Biosciences… (RKDA) | 100 | 0.8 | -99.2% |
| Linde plc (LIN) | 100 | 244.1 | +144.1% |
| Air Products and Ch… (APD) | 100 | 122.1 | +22.1% |
| Precigen, Inc. (PGEN) | 100 | 188.6 | +88.6% |
Price return only. Dividends and distributions are not included.
Quick Verdict: RKDA vs LIN vs APD vs PGEN
Each card shows where this stock fits in a portfolio — not just who wins on paper.
RKDA lags the leaders in this set but could rank higher in a more targeted comparison.
LIN carries the broadest edge in this set and is the clearest fit for growth exposure and long-term compounding.
- Rev growth 3.0%, EPS growth 7.1%, 3Y rev CAGR 0.6%
- 375.2% 10Y total return vs APD's 166.4%
- Lower volatility, beta 0.24, Low D/E 67.9%, current ratio 0.88x
- 3.0% revenue growth vs PGEN's -36.9%
APD is the #2 pick in this set and the best alternative if income & stability and defensive is your priority.
- Dividend streak 29 yrs, beta 0.45, yield 2.4%
- Beta 0.45, yield 2.4%, current ratio 1.38x
- Better valuation composite
- 2.4% yield, 29-year raise streak, vs LIN's 1.2%, (2 stocks pay no dividend)
PGEN is the clearest fit if your priority is momentum.
- +207.4% vs RKDA's -74.4%
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 3.0% revenue growth vs PGEN's -36.9% | |
| Value | Better valuation composite | |
| Quality / Margins | 20.6% margin vs PGEN's -39.1% | |
| Stability / Safety | Beta 0.24 vs PGEN's 1.44 | |
| Dividends | 2.4% yield, 29-year raise streak, vs LIN's 1.2%, (2 stocks pay no dividend) | |
| Momentum (1Y) | +207.4% vs RKDA's -74.4% | |
| Efficiency (ROA) | 8.3% ROA vs PGEN's -144.1%, ROIC 11.3% vs -152.8% |
RKDA vs LIN vs APD vs PGEN — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
RKDA vs LIN vs APD vs PGEN — Financial Metrics
Side-by-side numbers across 4 stocks — who leads on profitability, valuation, growth, and risk.
Who Leads Where
LIN leads in 2 of 6 categories
PGEN leads 1 • APD leads 1 • RKDA leads 0 • 2 tied
Explore the data ↓Income & Cash Flow (Last 12 Months)
LIN leads this category, winning 4 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
LIN is the larger business by revenue, generating $34.7B annually — 7133.6x RKDA's $5M. LIN is the more profitable business, keeping 20.6% of every revenue dollar as net income compared to PGEN's -39.1%. On growth, PGEN holds the edge at +2.1% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | ||||
|---|---|---|---|---|
| RevenueTrailing 12 months | $5M | $34.7B | $12.5B | $6M |
| EBITDAEarnings before interest/tax | -$2M | $12.1B | $3.9B | -$115M |
| Net IncomeAfter-tax profit | -$2M | $7.1B | $2.1B | -$247M |
| Free Cash FlowCash after capex | -$5M | $5.1B | $1.1B | -$76M |
| Gross MarginGross profit ÷ Revenue | +36.2% | +46.0% | +32.0% | +23.0% |
| Operating MarginEBIT ÷ Revenue | -51.4% | +28.8% | +18.4% | -18.6% |
| Net MarginNet income ÷ Revenue | -48.1% | +20.6% | +16.9% | -39.1% |
| FCF MarginFCF ÷ Revenue | -97.6% | +14.7% | +8.9% | -12.0% |
| Rev. Growth (YoY)Latest quarter vs prior year | -25.9% | +8.2% | +8.8% | +2.1% |
| EPS Growth (YoY)Latest quarter vs prior year | +16.9% | +13.4% | +141.1% | -11.7% |
Valuation Metrics
Evenly matched — RKDA and APD each lead in 2 of 5 comparable metrics.
Valuation Metrics
On an enterprise value basis, LIN's 19.7x EV/EBITDA is more attractive than APD's 119.7x.
| Metric | ||||
|---|---|---|---|---|
| Market CapShares × price | $2M | $228.8B | $65.7B | $1.2B |
| Enterprise ValueMkt cap + debt − cash | $1M | $250.8B | $82.2B | $1.2B |
| Trailing P/EPrice ÷ TTM EPS | -0.64x | 33.85x | -166.67x | -8.83x |
| Forward P/EPrice ÷ next-FY EPS est. | — | 27.67x | 22.46x | — |
| PEG RatioP/E ÷ EPS growth rate | — | 1.33x | — | — |
| EV / EBITDAEnterprise value multiple | — | 19.75x | 119.66x | — |
| Price / SalesMarket cap ÷ Revenue | 0.31x | 6.73x | 5.46x | 309.66x |
| Price / BookPrice ÷ Book value/share | 0.36x | 5.82x | 3.79x | 28.85x |
| Price / FCFMarket cap ÷ FCF | — | 44.97x | — | — |
Profitability & Efficiency
LIN leads this category, winning 6 of 9 comparable metrics.
Profitability & Efficiency
LIN delivers a 17.8% return on equity — every $100 of shareholder capital generates $18 in annual profit, vs $-6 for PGEN. PGEN carries lower financial leverage with a 0.14x debt-to-equity ratio, signaling a more conservative balance sheet compared to APD's 1.06x. On the Piotroski fundamental quality scale (0–9), LIN scores 6/9 vs APD's 2/9, reflecting solid financial health.
| Metric | ||||
|---|---|---|---|---|
| ROE (TTM)Return on equity | -40.6% | +17.8% | +11.9% | -5.9% |
| ROA (TTM)Return on assets | -26.1% | +8.3% | +5.1% | -144.1% |
| ROICReturn on invested capital | -2.5% | +11.3% | -2.0% | -152.8% |
| ROCEReturn on capital employed | -129.5% | +13.0% | -2.4% | -107.2% |
| Piotroski ScoreFundamental quality 0–9 | 2 | 6 | 2 | 3 |
| Debt / EquityFinancial leverage | — | 0.68x | 1.06x | 0.14x |
| Net DebtTotal debt minus cash | -$259,000 | $21.9B | $16.6B | -$24M |
| Cash & Equiv.Liquid assets | $259,000 | $5.1B | $1.9B | $30M |
| Total DebtShort + long-term debt | $0 | $27.0B | $18.4B | $6M |
| Interest CoverageEBIT ÷ Interest expense | — | 34.52x | 12.00x | -273.83x |
Total Returns (Dividends Reinvested)
PGEN leads this category, winning 3 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in LIN five years ago would be worth $17,394 today (with dividends reinvested), compared to $106 for RKDA. Over the past 12 months, PGEN leads with a +207.4% total return vs RKDA's -74.4%. The 3-year compound annual growth rate (CAGR) favors PGEN at 49.2% vs RKDA's -44.4% — a key indicator of consistent wealth creation.
| Metric | ||||
|---|---|---|---|---|
| YTD ReturnYear-to-date | -48.8% | +15.5% | +19.2% | -3.0% |
| 1-Year ReturnPast 12 months | -74.4% | +11.2% | +14.2% | +207.4% |
| 3-Year ReturnCumulative with dividends | -82.8% | +39.7% | +7.0% | +232.0% |
| 5-Year ReturnCumulative with dividends | -98.9% | +73.9% | +13.2% | -36.5% |
| 10-Year ReturnCumulative with dividends | -99.9% | +375.2% | +166.4% | -84.6% |
| CAGR (3Y)Annualised 3-year return | -44.4% | +11.8% | +2.3% | +49.2% |
Risk & Volatility
Evenly matched — LIN and APD each lead in 1 of 2 comparable metrics.
Risk & Volatility
LIN is the less volatile stock with a 0.24 beta — it tends to amplify market swings less than PGEN's 1.44 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. APD currently trades 96.0% from its 52-week high vs RKDA's 16.4% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | ||||
|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.98x | 0.24x | 0.45x | 1.44x |
| 52-Week HighHighest price in past year | $6.71 | $521.28 | $307.29 | $5.23 |
| 52-Week LowLowest price in past year | $1.01 | $387.78 | $229.11 | $1.23 |
| % of 52W HighCurrent price vs 52-week peak | +16.4% | +94.7% | +96.0% | +79.3% |
| RSI (14)Momentum oscillator 0–100 | 42.3 | 51.7 | 55.0 | 62.7 |
| Avg Volume (50D)Average daily shares traded | 35K | 2.3M | 1.2M | 4.3M |
Analyst Outlook
APD leads this category, winning 2 of 2 comparable metrics.
Analyst Outlook
Analyst consensus: LIN as "Buy", APD as "Buy", PGEN as "Buy". Consensus price targets imply 44.6% upside for PGEN (target: $6) vs 6.0% for APD (target: $313). For income investors, APD offers the higher dividend yield at 2.41% vs LIN's 1.21%.
| Metric | ||||
|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | Buy | Buy | Buy |
| Price TargetConsensus 12-month target | — | $539.71 | $312.78 | $6.00 |
| # AnalystsCovering analysts | — | 28 | 42 | 16 |
| Dividend YieldAnnual dividend ÷ price | — | +1.2% | +2.4% | — |
| Dividend StreakConsecutive years of raises | 1 | 6 | 29 | — |
| Dividend / ShareAnnual DPS | — | $6.00 | $7.11 | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | +2.0% | 0.0% | 0.0% |
LIN leads in 2 of 6 categories (Income & Cash Flow, Profitability & Efficiency). PGEN leads in 1 (Total Returns). 2 tied.
RKDA vs LIN vs APD vs PGEN: Key Questions Answered
10 questions · data-driven answers · updated daily
01Is RKDA or LIN or APD or PGEN a better buy right now?
For growth investors, Linde plc (LIN) is the stronger pick with 3.
0% revenue growth year-over-year, versus -36. 9% for Precigen, Inc. (PGEN). Linde plc (LIN) offers the better valuation at 33. 8x trailing P/E (27. 7x forward), making it the more compelling value choice. Analysts rate Linde plc (LIN) a "Buy" — based on 28 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — RKDA or LIN or APD or PGEN?
On forward P/E, Air Products and Chemicals, Inc.
is actually cheaper at 22. 5x — notably different from the trailing picture, reflecting expected earnings growth.
03Which is the better long-term investment — RKDA or LIN or APD or PGEN?
Over the past 5 years, Linde plc (LIN) delivered a total return of +73.
9%, compared to -98. 9% for Arcadia Biosciences, Inc. (RKDA). Over 10 years, the gap is even starker: LIN returned +375. 2% versus RKDA's -99. 9%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — RKDA or LIN or APD or PGEN?
By beta (market sensitivity over 5 years), Linde plc (LIN) is the lower-risk stock at 0.
24β versus Precigen, Inc. 's 1. 44β — meaning PGEN is approximately 500% more volatile than LIN relative to the S&P 500. On balance sheet safety, Precigen, Inc. (PGEN) carries a lower debt/equity ratio of 14% versus 106% for Air Products and Chemicals, Inc. — giving it more financial flexibility in a downturn.
05Which is growing faster — RKDA or LIN or APD or PGEN?
By revenue growth (latest reported year), Linde plc (LIN) is pulling ahead at 3.
0% versus -36. 9% for Precigen, Inc. (PGEN). On earnings-per-share growth, the picture is similar: Arcadia Biosciences, Inc. grew EPS 66. 9% year-over-year, compared to -110. 3% for Air Products and Chemicals, Inc.. Over a 3-year CAGR, LIN leads at 0. 6% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — RKDA or LIN or APD or PGEN?
Linde plc (LIN) is the more profitable company, earning 20.
3% net margin versus -32. 2% for Precigen, Inc. — meaning it keeps 20. 3% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: LIN leads at 26. 3% versus -34. 4% for PGEN. At the gross margin level — before operating expenses — LIN leads at 43. 3%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is RKDA or LIN or APD or PGEN more undervalued right now?
On forward earnings alone, Air Products and Chemicals, Inc.
(APD) trades at 22. 5x forward P/E versus 27. 7x for Linde plc — 5. 2x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for PGEN: 44. 6% to $6. 00.
08Which pays a better dividend — RKDA or LIN or APD or PGEN?
In this comparison, APD (2.
4% yield), LIN (1. 2% yield) pay a dividend. RKDA, PGEN do not pay a meaningful dividend and should not be held primarily for income.
09Is RKDA or LIN or APD or PGEN better for a retirement portfolio?
For long-horizon retirement investors, Linde plc (LIN) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.
24), 1. 2% yield, +375. 2% 10Y return). Both have compounded well over 10 years (LIN: +375. 2%, PGEN: -84. 6%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between RKDA and LIN and APD and PGEN?
These companies operate in different sectors (RKDA (Basic Materials) and LIN (Basic Materials) and APD (Basic Materials) and PGEN (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.
LIN, APD pay a dividend while RKDA, PGEN do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.